These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 30625462)

  • 1. Dexlansoprazole is Effective in Relieving Heartburn during the Fasting Month of Ramadan.
    Rimmani HH; Rustom LBO; Rahal MA; Shayto RH; Chaar H; Sharara AI
    Dig Dis; 2019; 37(3):188-193. PubMed ID: 30625462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dexlansoprazole for Heartburn Relief in Adolescents with Symptomatic, Nonerosive Gastro-esophageal Reflux Disease.
    Gold BD; Pilmer B; KierkuĊ› J; Hunt B; Perez MC; Gremse D
    Dig Dis Sci; 2017 Nov; 62(11):3059-3068. PubMed ID: 28916953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro-oesophageal reflux disease.
    Peura DA; Pilmer B; Hunt B; Mody R; Perez MC
    Aliment Pharmacol Ther; 2013 Nov; 38(10):1303-11. PubMed ID: 24118079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maintenance of heartburn relief after step-down from twice-daily proton pump inhibitor to once-daily dexlansoprazole modified release.
    Fass R; Inadomi J; Han C; Mody R; O'Neil J; Perez MC
    Clin Gastroenterol Hepatol; 2012 Mar; 10(3):247-53. PubMed ID: 22155561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease.
    Fass R; Chey WD; Zakko SF; Andhivarothai N; Palmer RN; Perez MC; Atkinson SN
    Aliment Pharmacol Ther; 2009 Jun; 29(12):1261-72. PubMed ID: 19392864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of increasing body mass index on heartburn severity, frequency and response to treatment with dexlansoprazole or lansoprazole.
    Peura DA; Pilmer B; Hunt B; Mody R; Perez MC
    Aliment Pharmacol Ther; 2013 Apr; 37(8):810-8. PubMed ID: 23451835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy of 60-mg dexlansoprazole and 40-mg esomeprazole after 24 weeks for the on-demand treatment of gastroesophageal reflux disease grades A and B: a prospective randomized trial.
    Chiang HH; Wu DC; Hsu PI; Kuo CH; Tai WC; Yang SC; Wu KL; Yao CC; Tsai CE; Liang CM; Wang YK; Wang JW; Huang CF; Chuah SK;
    Drug Des Devel Ther; 2019; 13():1347-1356. PubMed ID: 31118571
    [No Abstract]   [Full Text] [Related]  

  • 8. Dual Delayed-Release Dexlansoprazole for Healing and Maintenance of Healed Erosive Esophagitis: A Safety Study in Adolescents.
    Gremse D; Gold BD; Pilmer B; Hunt B; Korczowski B; Perez MC
    Dig Dis Sci; 2019 Feb; 64(2):493-502. PubMed ID: 30390234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis.
    Metz DC; Howden CW; Perez MC; Larsen L; O'Neil J; Atkinson SN
    Aliment Pharmacol Ther; 2009 Apr; 29(7):742-54. PubMed ID: 19210298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indirect comparison of randomised controlled trials: comparative efficacy of dexlansoprazole vs. esomeprazole in the treatment of gastro-oesophageal reflux disease.
    Wu MS; Tan SC; Xiong T
    Aliment Pharmacol Ther; 2013 Jul; 38(2):190-201. PubMed ID: 23718547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease.
    Liang CM; Kuo MT; Hsu PI; Kuo CH; Tai WC; Yang SC; Wu KL; Wang HM; Yao CC; Tsai CE; Wang YK; Wang JW; Huang CF; Wu DC; Chuah SK;
    World J Gastroenterol; 2017 Dec; 23(47):8395-8404. PubMed ID: 29307999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of acid-lowering drugs for endoscopy negative reflux disease: Systematic review and network Meta-Analysis.
    Barberio B; Visaggi P; Savarino E; de Bortoli N; Black CJ; Ford AC
    Neurogastroenterol Motil; 2023 Jan; 35(1):e14469. PubMed ID: 36153790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dexlansoprazole in the treatment of esophagitis and gastroesophageal reflux disease.
    Abel C; Desilets AR; Willett K
    Ann Pharmacother; 2010 May; 44(5):871-7. PubMed ID: 20371754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the efficiency of two different proton pump inhibitor formula in treatment of patients with atypical gastroesophageal reflux disease: a prospective randomized study.
    Lin XH; Luo JC; Ting PH; Chang TE; Huang YH; Hou MC; Lee FY
    J Gastroenterol Hepatol; 2020 Dec; 35(12):2096-2102. PubMed ID: 32401385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of dexlansoprazole MR on nocturnal heartburn and GERD-related sleep disturbances in patients with symptomatic GERD.
    Fass R; Johnson DA; Orr WC; Han C; Mody R; Stern KN; Pilmer BL; Perez MC
    Am J Gastroenterol; 2011 Mar; 106(3):421-31. PubMed ID: 21224838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fragments of e-Cadherin as Biomarkers of Non-erosive Reflux Disease.
    Jovov B; Reed CC; Shaheen NJ; Pruitt A; Ferrell K; Orlando GS; Djukic Z; Orlando RC
    Dig Dis Sci; 2018 Mar; 63(3):628-635. PubMed ID: 29071486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised clinical trial: sodium alginate oral suspension is non-inferior to omeprazole in the treatment of patients with non-erosive gastroesophageal disease.
    Chiu CT; Hsu CM; Wang CC; Chang JJ; Sung CM; Lin CJ; Chen LW; Su MY; Chen TH
    Aliment Pharmacol Ther; 2013 Nov; 38(9):1054-64. PubMed ID: 24024757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting the efficacy of proton pump inhibitors in patients with non-erosive reflux disease before therapy using dual-channel 24-h esophageal pH monitoring.
    Shimatani T; Sugimoto M; Nishino M; Adachi K; Furuta K; Ito M; Kurosawa S; Manabe N; Mannen K; Hongo M; Chiba T; Kinoshita Y;
    J Gastroenterol Hepatol; 2012 May; 27(5):899-906. PubMed ID: 22098590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dexlansoprazole for the treatment of esophagitis and GERD.
    Davies SL
    Drugs Today (Barc); 2010 Feb; 46(2):75-80. PubMed ID: 20393635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised clinical trial: the clinical efficacy and safety of an alginate-antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China.
    Sun J; Yang C; Zhao H; Zheng P; Wilkinson J; Ng B; Yuan Y
    Aliment Pharmacol Ther; 2015 Oct; 42(7):845-54. PubMed ID: 26228097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.